The latest price target for Pyxis Oncology (NASDAQ:PYXS) was reported by HC Wainwright & Co. on December 20, 2024. The analyst firm set a price target for $5.00 expecting PYXS to rise to within 12 months (a possible 195.86% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Pyxis Oncology (NASDAQ:PYXS) was provided by HC Wainwright & Co., and Pyxis Oncology reiterated their buy rating.

There is no last upgrade for Pyxis Oncology

The last downgrade for Pyxis Oncology Inc happened on November 21, 2024 when William Blair changed their price target from N/A to N/A for Pyxis Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pyxis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pyxis Oncology was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest Pyxis Oncology (PYXS) rating was a reiterated with a price target of $7.00 to $5.00. The current price Pyxis Oncology (PYXS) is trading at is $1.69, which is out of the analyst’s predicted range.